samedan logo

 
 
spacer
home > pmps > autumn 2003 > outsourced development and production; speed in development plus strength in manufacturing equals success in bio/pharma: bio/phardos and bio/pharmos 2004
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Outsourced Development and Production; Speed in Development Plus Strength in Manufacturing Equals Success in Bio/Pharma: Bio/PharDOS and Bio/PharMOS 2004

With the launch of Bio/PharDOS, a new niche event to fill a gap in the market for development outsourcing services across the biotech and pharma value chain, is it time to look at the business prospects for this sector? What are the practical issues to be addressed in taking innovative products from discovery through the development pipeline and into commercial manufacturing? How will these challenges be faced by the industry? When can the market expect to see decent returns? These are weighty issues indeed! Answers are not intuitively obvious; even the sector's analysts are playing a game of 'wait and see' while investors in life science sit on their hands or their wallets waiting for better times ahead.

Judging by the volume of leaflets in the post and any number of emails on the subject of 'pharma outsourcing', one might wonder if this has become the burning 'hot issue' for the industry. It's nonsense of course. Since a golden hey-day, way back in 2000, numerous pharma and biotechnology events have experienced dwindling audiences. Some event organisers, aware of the success enjoyed by specialist, niche shows specifically set up for outsourcing service providers, especially in manufacturing, have tacked the magic 'O' label on to somewhat tired looking events hoping this trick might draw a bigger audience out of the hat. Others have opted to combine or to co-locate different events into a single, 'one-stop shop', primarily as a cost-cutting exercise.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Charles Horth, Life Science Consulting Editor at Cytops

Dr Charles Horth is Life Science Consulting Editor at Cytops, UK. Having gained a PhD in Biochemical Pharmacology, Charles has spent over 30 years in the life science industry after training in biochemistry, medical biochemistry and physiology. His industrial career began with market research in biotechnology, followed by laboratory instrument development. He subsequently worked for Vitamins Research (now part of GSK), CIBA-Geigy in Basel, Switzerland (now Novartis) and Searle, UK (now Pharmacia/Pfizer). Charles helped to set up and market a contract laboratory service for bioanalytical testing, metabolism studies, diagnostics and clinical development services. Charles provides professional advisory services for the pharma, biotech and nutraceuticals sector for a number of European clients. He writes for biotech and pharma publications, has published over 40 scientific articles and was Managing Editor of BioPharmaWeb at VerticalNet Europe and Editor of Life Science Today.

spacer
Dr Charles Horth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Rentschler Biopharma awarded Chiesi Supplier Award


More info >>

White Papers

Environmental Factors in Data Centres

Dycem

In addition to temperature and humidity, there are many more constraints in the environment that increase failure rates, explains Emilio Sapiņa of Secure Techincal Rooms.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement